|
US 12,029,785 B2 |
|
| GINS2 peptide and T cells for use in immunotherapeutic treatment of various cancers |
| Andrea Mahr, Tuebingen (DE); Toni Weinschenk, Tuebingen (DE); Oliver Schoor, Tuebingen (DE); Jens Fritsche, Tuebingen (DE); and Harpreet Singh, Tuebingen (DE) |
| Assigned to Immatics Biotechnologies GmbH, (DE) |
| Filed by Immatics Biotechnologies GmbH, Tuebingen (DE) |
| Filed on Feb. 18, 2022, as Appl. No. 17/675,530. |
| Application 17/675,530 is a continuation of application No. 17/320,763, filed on May 14, 2021, granted, now 11,793,866. |
| Application 17/320,763 is a continuation of application No. 17/017,358, filed on Sep. 10, 2020, granted, now 11,065,316, issued on Jul. 20, 2021. |
| Application 17/017,358 is a continuation of application No. 16/887,765, filed on May 29, 2020, granted, now 10,898,557, issued on Jan. 26, 2021. |
| Application 16/887,765 is a continuation of application No. 16/673,619, filed on Nov. 4, 2019, granted, now 10,695,411, issued on Jun. 30, 2020. |
| Application 16/673,619 is a continuation of application No. 15/982,293, filed on May 17, 2018, granted, now 10,576,132, issued on Mar. 3, 2020. |
| Application 15/982,293 is a continuation of application No. 15/249,083, filed on Aug. 26, 2016, granted, now 10,335,471, issued on Jul. 2, 2019. |
| Claims priority of provisional application 62/211,276, filed on Aug. 28, 2015. |
| Claims priority of application No. 1515321 (GB), filed on Aug. 28, 2015. |
| Prior Publication US 2022/0249630 A1, Aug. 11, 2022 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/115 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01) |